| Literature DB >> 22916713 |
Arjan A van de Loosdrecht1, Robin Ireland, Wolfgang Kern, Matteo G Della Porta, Canan Alhan, Jan Sebastian Balleisen, Peter Bettelheim, David T Bowen, Kate Burbury, Lisa Eidenschink, Mario Cazzola, Spencer S C Chu, Matthew Cullen, Jevon A Cutler, Angelika M Dräger, Jean Feuillard, Pierre Fenaux, Patricia Font, Ulrich Germing, Detlef Haase, Eva Hellström-Lindberg, Ulrika Johansson, Shahram Kordasti, Michael R Loken, Luca Malcovati, Jeroen G te Marvelde, Sergio Matarraz, Timothy Milne, Bijan Moshaver, Ghulam J Mufti, Veselka Nikolova, Kiyoyuki Ogata, Uta Oelschlaegel, Alberto Orfao, Gert J Ossenkoppele, Anna Porwit, Uwe Platzbecker, Frank Preijers, Katherina Psarra, Stephen J Richards, Dolores Subirá, John F Seymour, Vicky Tindell, Teresa Vallespi, Peter Valent, Vincent H J van der Velden, Denise A Wells, Theo M de Witte, Florian Zettl, Marie C Béné, Theresia M Westers.
Abstract
An international working group within the European LeukemiaNet gathered, aiming to determine the role of flow cytometry (FC) in myelodysplastic syndromes (MDS). It was agreed that FC has a substantial application in disease characterization, diagnosis and prognosis. FC may also be useful in predicting treatment responses and monitoring novel and standard therapeutic regimens. In this article the rationale is discussed that flow cytometry should be integrated as a part of diagnostic and prognostic scoring systems in MDS.Entities:
Mesh：
Year: 2012 PMID： 22916713 DOI： 10.3109/10428194.2012.718341
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022